Stratos Wealth Advisors LLC Invests $2.02 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Stratos Wealth Advisors LLC bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 83,475 shares of the biopharmaceutical company's stock, valued at approximately $2,024,000. Stratos Wealth Advisors LLC owned approximately 0.07% of Catalyst Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in CPRX. Steward Partners Investment Advisory LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $27,000. Park Square Financial Group LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at about $29,000. Farther Finance Advisors LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after purchasing an additional 1,495 shares in the last quarter. Sound Income Strategies LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the first quarter valued at about $64,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after purchasing an additional 579 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Preethi Sundaram sold 2,324 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total transaction of $61,376.84. Following the completion of the transaction, the insider owned 42,681 shares of the company's stock, valued at approximately $1,127,205.21. This represents a 5.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Gary Ingenito sold 200,000 shares of the company's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the transaction, the insider directly owned 68,873 shares of the company's stock, valued at $1,630,912.64. This trade represents a 74.38% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 247,924 shares of company stock valued at $5,879,369 in the last ninety days. 10.40% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Stock Up 4.2%

Shares of NASDAQ:CPRX traded up $0.88 during trading on Wednesday, reaching $21.63. The stock had a trading volume of 1,479,057 shares, compared to its average volume of 1,124,123. The business has a fifty day moving average price of $23.61 and a 200-day moving average price of $22.89. The stock has a market cap of $2.64 billion, a P/E ratio of 13.78, a PEG ratio of 0.85 and a beta of 0.66. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $15.19 and a fifty-two week high of $26.58.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Six equities research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $32.83.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.